BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/27/2015 4:29:00 PM | Browse: 1189 | Download: 1736
 |
Received |
|
2014-08-16 10:43 |
|
Peer-Review Started |
|
2014-08-16 19:21 |
|
To Make the First Decision |
|
2014-09-15 16:14 |
|
Return for Revision |
|
2014-09-17 22:33 |
|
Revised |
|
2014-09-30 22:47 |
|
Second Decision |
|
2014-10-21 17:32 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2014-10-21 18:02 |
|
Articles in Press |
|
2014-10-21 18:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2014-10-31 09:46 |
|
Typeset the Manuscript |
|
2015-04-14 10:00 |
|
Publish the Manuscript Online |
|
2015-04-27 16:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Value of bevacizumab in treatment of colorectal cancer: A meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chun-Ying Qu, Ying Zheng, Min Zhou, Yi Zhang, Feng Shen, Jia Cao and Lei-Ming Xu |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lei-Ming Xu, Chief Physician, Department of Digestive Diseases, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai 200092, China. leiming.xu@aliyun.com |
| Key Words |
Bevacizumab; Colorectal cancer; Clinical application; Randomized controlled trials; Meta-analysis |
| Core Tip |
Bevacizumab combined with chemotherapy can provide a significant survival advantage in patients with colorectal cancer. Despite the increased risk of hypertension, proteinuria, bleeding, thrombosis, gastrointestinal perforation and other adverse events, bevacizumab combined with chemotherapy deserves further promotion in future clinical work due to its low incidence of serious adverse events, excellent overall tolerance and good safety. |
| Publish Date |
2015-04-27 16:22 |
| Citation |
Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(16): 5072-5080 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i16/5072.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i16.5072 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
